Filing Details

Accession Number:
0001179022-16-000099
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-04-21 19:35:21
Reporting Period:
2016-04-19
Filing Date:
2016-04-21
Accepted Time:
2016-04-21 19:35:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1133416 Galectin Therapeutics Inc GALT Pharmaceutical Preparations (2834) 043562325
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1453356 10X Fund, L.p. 1230 Peachtree St. Ne
Ste. 2445
Atlanta GA 30309
No No Yes No
1457247 10X Capital Management, Llc 1230 Peachtree St. Ne
Ste. 2445
Atlanta GA 30309
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-04-19 33,100 $1.70 3,271,909 No 4 S Direct
Common Stock Disposition 2016-04-20 11,212 $1.59 3,260,697 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Footnotes
  1. Reflects weighted average price. Range of prices were between $1.69 and $1.715. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
  2. Reflects weighted average price. Range of prices were between $1.55 and $1.62. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
  3. 10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. 10X Capital Management, LLC disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.